Access Bio
Access Bio is a privately held US-based consulting group (11–50 employees, Boyce) supporting drug, biological, and medical device product development, which in 2026 acquired RFTbio from RFTtech for ~57 billion won.
- Company typePrivate
- Founded-
- HeadquartersBoyce, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Access Bio does
Access Bio is a privately held, small-scale firm (11–50 employees) headquartered in Boyce, United States, described in firmographic data as a consulting group that assists in the development of drug, biological, and medical device products. The available source material does not disclose its product portfolio, pricing model, go-to-market motion, customer segments, or revenue mechanics — the firm's website (accessbio.com) appears as a placeholder/parked domain in the captured content, and no substantive service or technology description is available from primary sources.
The most substantive documented activity is a 2026 acquisition: Access Bio acquired RFTbio, a bio/biological products subsidiary divested by South Korean diversified technology group RFTtech, for approximately 57 billion won as part of RFTtech's reorganization to exit non-core affiliates following the failure of its diversification into bio, semiconductors, and secondary batteries. Following the transaction, Access Bio is described as having retained a partial 18.37% stake position in RFTbio. The combination of a US-headquartered consulting profile with a Korean-won-denominated acquisition raises a potential identity ambiguity that the available sources do not resolve.
No management team, employees, partnerships beyond the RFTbio transaction, certifications, patents, funding rounds, product launches, or technology stack details are disclosed. As a result, the business model, addressable market, and competitive positioning cannot be characterized beyond what is stated above.
Access Bio firmographics
Firmographics- Name
- Access Bio
- Website
- https://accessbio.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Access Bio is a privately held US-based consulting group (11–50 employees, Boyce) supporting drug, biological, and medical device product development, which in 2026 acquired RFTbio from RFTtech for ~57 billion won.
- Ownership category
- akta.pro rank
Access Bio industry classification
Industry- Product category
- Pharmaceutical and Life Sciences Consulting
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF)
Keywords
Where Access Bio is headquartered
LocationHeadquarters
- HQ city
- Boyce
- HQ country
- United States
- HQ region
- North America
Markets served
Access Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations
Access Bio product offering
Product offeringCore offering
Access Bio is a consulting group that assists clients in the development of drug, biological, and medical device products. The firm provides advisory services rather than manufacturing or selling its own end products. Beyond the consulting description, public sources also reference the company in an acquisition capacity, having acquired RFTbio from RFTtech for approximately 57 billion won.
Product overview
Based on the limited source data, Access Bio appears to be a company that acquired RFTbio from RFTtech for approximately 57 billion won. No substantive product portfolio, service offerings, or technology platform details are available in the provided sources.
Differentiator
Problem solved
Functional benefit
Products and services
- Drug Development Consulting Advisory and consulting support to organizations developing pharmaceutical drug products.
- Biological Product Development Consulting Consulting services supporting the development of biological products for client organizations.
- Medical Device Development Consulting Consulting and development support for organizations creating medical device products.
Companies that use Access Bio
Customer profileIdeal customer profiles1 record
Access Bio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Access Bio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- RFTtechcoreAccess Bio acquired RFTbio (a subsidiary of RFTtech) for approximately 57 billion won as part of RFTtech's reorganization strategy to shed non-core businesses. RFTtech sold the business to refocus on its core mobile equipment operations. Access Bio retained partial stake of 18.37% in RFTbio following the transaction.
Recent moves1 record
Expansion highlights2 records
Access Bio competitors and assessment
Company assessmentBroad incumbents
- Samsung Biologics: South Korea-headquartered global CDMO providing end-to-end biologics development and manufacturing services. Closely relevant peer to the RFTbio subsidiary and to the cross-border nature of Access Bio's recent acquisition from RFTtech.
- Catalent: Large global CDMO providing development, manufacturing, and consulting-related services across biologics, drugs, and medical devices. Comparable to Access Bio across multiple service lines, though at substantially greater scale.
- Charles River Laboratories: Major CRO and life sciences services provider with biological research, drug development, and consulting offerings. Comparable to Access Bio's drug and biological development consulting focus, though at significantly larger scale.
- IQVIA Holdings: Global leader in CRO and life sciences consulting with deep drug development and biological research capabilities. Directly comparable in service mix to Access Bio's consulting work for drug and biological product development.
- WuXi AppTec: Asia-headquartered global CRO/CDMO providing drug discovery, development, and manufacturing services. Comparable to Access Bio's consulting + bio products combination, though at much greater scale and broader geographic reach.
- ICON plc: Large global CRO providing drug and biological product development services across consulting, clinical, and post-approval. Comparable to Access Bio's consulting services though at meaningfully larger scale and broader geographic coverage.
Direct peers
- AGC Biologics: Global CDMO offering process development, manufacturing, and consulting-adjacent services for biological products. Most directly comparable to the bio products and development services that Access Bio delivers through RFTbio and its consulting arm.
- Parexel International: Mid-size global CRO providing drug and biological product development consulting and services. Closely comparable in business model and service mix to Access Bio's core consulting practice in drug and biological product development.
- Medpace: Mid-size CRO focused on clinical development services for drugs and biologics. Comparable to Access Bio's development consulting services for drug and biological products, and similarly positioned around specialized sponsor engagements.
- Syneos Health: Mid-size CRO providing drug and biologics development consulting and clinical services. Comparable in business model, customer base, and service mix to Access Bio's drug and biological product development consulting.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat1 record
Key risks5 records
Key highlights5 records
Customer concentration
Access Bio social profiles
Digital presenceAccess Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Access Bio leadership team
Management profileNumber of profiles
Access Bio subsidiaries and ownership
Company hierarchySubsidiaries1 record
Access Bio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Access Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Access Bio
What does Access Bio do?
Access Bio is a consulting group that assists clients in the development of drug, biological, and medical device products. The firm provides advisory services rather than manufacturing or selling its own end products. Beyond the consulting description, public sources also reference the company in an acquisition capacity, having acquired RFTbio from RFTtech for approximately 57 billion won.
Is Access Bio a public or private company?
Access Bio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Access Bio founded?
Access Bio was founded in -1. It employs 11 to 50 people.
Where is Access Bio based?
Access Bio is headquartered in Boyce, United States, in the North America region.
Who are Access Bio's main competitors?
Broad incumbents on record are Samsung Biologics, Catalent, Charles River Laboratories, IQVIA Holdings, WuXi AppTec and ICON plc. Direct peers are AGC Biologics, Parexel International, Medpace and Syneos Health.
Does Access Bio have an API?
No public API is recorded for Access Bio.
What industry is Access Bio in?
Access Bio's product category is Pharmaceutical and Life Sciences Consulting. Its primary akta.pro industry code is HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream). Its NAICS code is 54171 and its SIC code is 8731.